



## Development of a Video-Microscopic Tool To Evaluate the Precipitation Kinetics of Poorly Water Soluble Drugs: A Case Study with Tadalafil and HPMC

Christfort, Juliane Fjelrad; Plum, Jakob; Madsen, Cecilie Maria; Nielsen, Line Hagner; Sandau, Martin; Andersen, Klaus; Müllertz, Anette; Rades, Thomas

*Published in:*  
Molecular Pharmaceutics

*Link to article, DOI:*  
[10.1021/acs.molpharmaceut.7b00422](https://doi.org/10.1021/acs.molpharmaceut.7b00422)

*Publication date:*  
2017

*Document Version*  
Peer reviewed version

[Link back to DTU Orbit](#)

*Citation (APA):*  
Christfort, J. F., Plum, J., Madsen, C. M., Nielsen, L. H., Sandau, M., Andersen, K., Müllertz, A., & Rades, T. (2017). Development of a Video-Microscopic Tool To Evaluate the Precipitation Kinetics of Poorly Water Soluble Drugs: A Case Study with Tadalafil and HPMC. *Molecular Pharmaceutics*, 14(12), 4154–4160. <https://doi.org/10.1021/acs.molpharmaceut.7b00422>

---

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 **Development of a Video-Microscopic Tool to Evaluate the**  
2 **Precipitation Kinetics of Poorly-Water Soluble Drugs: A Case Study**  
3 **with Tadalafil and HPMC**

4 Juliane Fjelrad Christfort<sup>1\*</sup>, Jakob Plum<sup>1\*</sup>, Cecilie Maria Madsen<sup>1,†</sup>, Line Hagner Nielsen<sup>2</sup>, Martin  
5 Sandau<sup>3</sup>, Klaus Andersen<sup>3</sup>, Anette Müllertz<sup>1,4,‡</sup>, Thomas Rades<sup>1,5</sup>

6 1) Department of Pharmacy, University of Copenhagen, DK-2100 Copenhagen, Denmark

7 2) Department of Micro and Nanotechnology, Technical University of Denmark, DK-2800 Lyngby, Denmark

8 3) Philips BioCell A/S, DK-3450 Allerød, Denmark

9 4) Bioneer:FARMA, University of Copenhagen, DK-2100 Copenhagen, Denmark

10 5) Faculty of Science and Engineering, Åbo Akademi University, Tykistökatu 6A, 20521 Turku, Finland

11 *\*These authors contributed equally to the manuscript.*

12

13 *Keywords*

14 *supersaturation, precipitation, oral drug delivery, crystalline*

15


16 **Graphical abstract**

17

18

19

20



<sup>†</sup> Currently employed at Analytical Research and Development, H. Lundbeck A/S, Ottiliavej 9, Valby, Denmark

<sup>‡</sup> Correspondence to: Anette Müllertz

Department of Pharmacy,

University of Copenhagen,

Universitetsparken 2

DK-2100 Copenhagen, Denmark

Telephone: 0045 35336440; Fax: 0045 35336001.

E-mail address: anette.mullertz@sund.ku.dk

---

21 **Abstract**

22 Many drug candidates today have a low aqueous solubility, and hence may show a low oral  
23 bioavailability, presenting a major formulation and drug delivery challenge. One way to increase the  
24 bioavailability of these drugs is to use a supersaturating drug delivery strategy. The aim of this study  
25 was to develop a video-microscopic method, to evaluate the effect of a precipitation inhibitor on  
26 supersaturated solutions of the poorly soluble drug tadalafil, using a novel video microscopic small  
27 scale setup. Based on preliminary studies, a degree of supersaturation of 29 was chosen for the  
28 supersaturation studies with tadalafil in FaSSIF. Different amounts of HPMC were predissolved in  
29 FaSSIF to give four different concentrations, and the supersaturated system was then created using a  
30 solvent shift method. Precipitation of tadalafil from the supersaturated solutions was monitored by  
31 video-microscopy as a function of time. Single-particle analysis was possible using commercially  
32 available software, however, to investigate the entire population of precipitating particles (i.e. their  
33 number and area covered in the field of view) an image analysis algorithm was developed (multi-  
34 particle analysis). The induction time for precipitation of tadalafil in FaSSIF was significantly  
35 prolonged by adding 0.01 % (w/v) HPMC to FaSSIF, and the maximum inhibition was reached at 0.1  
36 % (w/v) HPMC, after which additional HPMC did not further increase the induction time. The single-  
37 and multi-particle analyses yielded the same ranking of the HPMC concentrations, regarding the  
38 inhibitory effect on precipitation. The developed small scale method to assess the effect of precipitation  
39 inhibitors can speed up the process of choosing the right precipitation inhibitor and the concentration to  
40 be used.

---

41 **1. Introduction**

42

43 It has been estimated that approximately 75 - 90 % of low molecular weight drug candidates in development can be considered  
44 poorly soluble in water (1-3), often leading to low and inconsistent bioavailability. Therefore, there is a growing need for  
45 formulation strategies enabling increased oral bioavailability. One such strategy is the use of supersaturating drug delivery systems  
46 which can induce supersaturation, e.g. in the small intestine (4, 5).

47 In a supersaturated system, the drug concentration exceeds the equilibrium solubility of the drug thus, increasing the free drug  
48 concentration available for absorption in the small intestine. According to Fick's law, an increased free drug concentration will  
49 lead to a higher flux and hence, a higher absorption. A common way to describe a supersaturated system is to use the degree of  
50 supersaturation (DS). DS is defined as the ratio between the concentration in the supersaturated solution and the thermodynamic  
51 equilibrium solubility of the drug in the same medium (6):

$$DS = \frac{C_{supersaturation}}{C_{equilibrium}} \quad (\text{Eq. 1})$$

Supersaturated systems are thermodynamically unstable and will inevitably be driven towards equilibrium solubility over time, which poses a significant challenge for the formulation work using such systems (4). In a supersaturated solution, the equilibrium will be restored by precipitation of the drug, which will, consequently, lower the free drug concentration available for absorption. The precipitation process can be split into two sub-processes, having their own kinetics, i.e. nucleation and crystal growth (7). Nucleation happens when molecules interact to form a cluster of a critical radius. This critical cluster formation requires a specific amount of energy. Once a nucleus has been formed and starts to grow, the process is irreversible and crystal growth occurs. Nucleation occurs prior to crystal growth; however, nucleation continues to occur following the formation of the first nucleus making it difficult to distinguish the nucleation and crystal growth kinetics from each other (7). The induction time ( $t_{ind}$ ), being the time point at which the first precipitate is formed, is often used as a proxy to describe the nucleation process. In case of a supersaturating drug delivery strategy, it is desired to prolong the time until precipitation, and hereby, the duration of the existence of a supersaturated system. This can be achieved by introducing an excipient to reduce or inhibit precipitation, a so called precipitation inhibitor (PI) (4). Polyvinylpyrrolidone (PVP) (8), (hydroxypropyl)methyl cellulose (HPMC) (9), and cyclodextrins such as sulfobutyl-ether  $\beta$ -cyclodextrin (10) are commonly used as PIs. The PIs act either by decreasing nucleation or crystal growth rate (or both) through various pathways (4). HPMC is often used as a PI in pharmaceutical studies (6, 10-12) and it has previously been shown to delay the onset of precipitation (i.e. to prolong  $t_{ind}$ ) of different drugs such as tadalafil (6), dapivirine (10), and RS-8359 (13). Several mechanisms of action have been proposed; the effect of HPMC may be due to hydrogen-bonding between the polymer and the drug (this would lead to a reduction in the nucleation kinetics) (9, 14), or adsorption of HPMC to the crystal surface of a growing crystal (this would reduce the crystal growth kinetics) (15). HPMC and other polymers may also work as precipitation inhibitors by increasing the viscosity of the dissolution medium, hereby reducing molecular mobility and diffusion coefficient of the precipitating drug (4). Addition of HPMC to the dissolution medium has also been shown to change the crystal structure of the precipitate of several drugs compared to a PI-free system (16), further indicating the presence of molecular interactions between the drug and the polymer during the precipitation process. It is generally known that the effect of a PI is very drug specific, and the optimal type and concentration of polymer to inhibit precipitation of a supersaturated solution will vary, depending on the drug of interest (8, 12, 17). Warren et al. (12) investigated combinations of 42 polymers and three drugs and found very different effects on the same drug depending on polymer type, concentration and grade used as PI. Hence, it will be necessary to test several polymers in different concentrations before choosing the optimal PI type, concentration and grade for a given drug, and therefore a high-throughput, small scale setup to study precipitation kinetics is highly needed.

Precipitation studies are conventionally performed in a regular dissolution setup where the drug concentration is monitored over time (18), and the detection of precipitation is often based on a decrease in drug concentration in solution and not on the formation of particles. A direct way of studying precipitation is the use of microscopic methods. The advantage of a microscopic approach is the direct visualization of the precipitate, instead of the use of a surrogate marker (concentration of dissolved drug using e.g. *in situ* UV measurements). This gives the opportunity to investigate the early stages of precipitation where the amount of precipitate is not sufficient for a baseline shift due to light scattering in the visible range of the electromagnetic spectrum.

Previously, microscopy has been used to investigate precipitation in supersaturated gels over a period of days (9). Conventional microscopy, however, is time consuming and labour intensive, and therefore more automated methods have been developed for different purposes. For example, Wu et al. (19) have developed a method for online monitoring of nucleation and crystal growth using polarized light microscopy and subsequent image analysis, and recently, a method describing single pellet dissolution in a 24-well plate using video-microscopy has been published, and it was found that this method had an excellent correlation to UV measurements (20).

The combination of conventional microscopy and video analysis has furthermore been used for investigations of bacterial growth (21), in a commercially available 96-well plate setup called the oCelloScope™, specifically developed for this purpose. The aim of the current study was to develop a video-microscopic tool to screen for the effect of PIs for early drug development using this equipment. The model systems consisted of supersaturated solutions of the poorly-water soluble drug tadalafil and HPMC as PI.

## 2. Materials and Methods

### 2.1 Materials

Fasted state simulated intestinal fluid (FaSSIF) powder was purchased from biorelevant.com (London, UK). Tadalafil was purchased from AK Scientific (Union City, Ca, USA). Sodium chloride, monobasic sodium phosphate dihydrate and dimethyl

105 sulfoxide (DMSO) were acquired from Merck Millipore (Darmstadt, Germany). Sodium hydroxide was obtained from VWR  
106 Chemicals (Leuven, Belgium) and hydroxypropyl methyl cellulose (HPMC, Pharmacoat 606 6 cp) was purchased from Shin Etsu  
107 (Tokyo, Japan). Nunc 96-well microplates with Nunclon Delta Surface were obtained from Thermo Fisher Scientific (Waltham,  
108 MA, USA). Q-max RR syringe filters were acquired from Frisenette (Knebel, Denmark).

## 110 2.2 Methods

### 111 2.2.1 Equilibrium solubility of tadalafil

112 The solubility of tadalafil in FaSSIF + 13 % (v/v) DMSO and FaSSIF + 13 % (v/v) DMSO + HPMC in increasing  
113 concentrations were investigated using a shake-flask method at room temperature. FaSSIF containing 13 % (v/v) DMSO was  
114 prepared by adding 1.5 mL DMSO to 10 mL of FaSSIF. Then excess tadalafil (>10x equilibrium solubility) was added. The  
115 suspension was shaken for 24 h and samples were taken at three time points during the experiment (3 h, 22 h and 24 h after  
116 starting the experiment). The samples were filtered through a 0.22  $\mu\text{m}$  PTFE Hydrophilic filter (Q-Max RR Syringe Filter) prior to  
117 quantification by high-performance liquid chromatography (HPLC). All experiments were performed in triplicate. Analysis was  
118 performed on a C18 column (Kinetix XB-C18, 5 $\mu\text{m}$ , Phenomenex, (Torrance, California, U.S)) with a mobile phase of 0.1 % (v/v)  
119 trifluoroacetic acid in 40:60 acetonitrile:water (v/v) in a Dionex HPLC with UV detection at 284 nm.

### 121 2.2.2 Preparation of a supersaturated tadalafil solution in FaSSIF

122 FaSSIF was prepared according to the instructions of the manufacturer and HPMC (0.0 – 0.5 % w/v) was added. The mix was  
123 stirred overnight in order for the polymer to equilibrate in the medium (22).

124 The studies were conducted in 96-well microplates at room temperature by spiking 30  $\mu\text{L}$  of a tadalafil-DMSO stock solution (5  
125 mg/mL) into 200  $\mu\text{L}$  FaSSIF with or without predissolved HPMC, to induce a supersaturated tadalafil solution with a  
126 concentration of 652  $\mu\text{g/mL}$  (DS = 29). The solution was mixed by pipetting up and down two times when spiking tadalafil into  
127 the FaSSIF filled well. The molecular weight of HPMC was 36 kDa (23) and the molar drug:polymer ratio spanned from 14-7030.

### 129 2.2.3 oCelloScope<sup>TM</sup> setup

130 The precipitation studies were performed on an oCelloScope System<sup>TM</sup> (Philips Biocell A/S, Allerød, Denmark). This system is  
131 a video-microscopic setup creating a series of micrographs using time-lapse technology, as described by Fredborg et al. (21). The  
132 experiments were performed in 24 replicates for each HPMC concentration. For obtaining 24 replicates in total, 3 or 4 experiments  
133 were run simultaneously 8 or 6 times. The illumination level and focus were set manually and adjusted individually before each  
134 experiment to ensure high micrograph quality for the subsequent image analysis. The illumination level interval varied from 300-  
135 400 and the focus from 2800-2990 depending on the experiment, and the illumination time was kept constant at 2 ms throughout  
136 all experiments. Twenty micrographs were acquired of each well at every time point creating an 855  $\mu\text{m}$  length of the scan and  
137 thereby, covering 1.49  $\text{mm}^2$  of the well. The number of repetitions and the repetition intervals were chosen depending on the  
138 concentration of HPMC, and designed to cover a period of 22 min. Around the  $t_{\text{ind}}$ , micrographs were acquired every 20 s.

### 140 2.2.4 Single-particle analysis

141 Micrographs acquired by the oCelloScope<sup>TM</sup> were analysed with the UniExplorer software version 6.0, accompanying the  
142 equipment (Philips Biocell A/S, Allerød, Denmark). Using the segmentation tool in UniExplorer software, the areas of the  
143 individual particles for every measurement time point were calculated. The  $t_{\text{ind}}$  was determined as the time point where the  
144 software identified the first particle in focus. Crystal growth was determined from the area of one well-defined particle, often the  
145 first particle to appear, calculated by the software. The particle areas were exported and further data treatment was performed  
146 using Excel 2010 (Microsoft Office, Wa, USA). Visualization and statistical analysis were performed using GraphPad Prism  
147 version 6.0 (GraphPad software Inc. Ca, USA). Statistical differences were determined using one-way ANOVA with a Sidak  
148 multiple comparison test.

### 150 2.2.5 Multi-particle analysis

151 In contrast to the single-particle analysis, multi-particle analysis determined crystal growth from the area of *all* the particles  
152 precipitating within the field of view. The areas covered by particles were segmented using UniExplorer's gradient segmentation  
153 algorithm and the H-minima Transform algorithm (24). From the segmented areas, crystal growth was then quantified as the  
154 percentage of the total micrograph area covered by the particles and as the number of particles. The number of particles was  
155 counted automatically using the two stage circular Hough transform (25). With this approach circles were fitted to the segmented  
156 areas, where the number of fitted circles corresponded to the number of particles in the micrograph.

157 **3. Results and Discussion**


158  
159 3.1 Solubility, micrograph quality and morphology

160 The equilibrium solubility of tadalafil was investigated in FaSSIF containing 13 % (v/v) DMSO with and without addition of up  
161 to 1 % (w/v) HPMC. The solubility was found to be  $22.5 \pm 1.6 \mu\text{g/mL}$ , and addition of HPMC did not increase the solubility  
162 significantly ( $p > 0.05$ ).

163 The precipitation kinetics of the supersaturated tadalafil solutions were monitored using the oCelloScope™ set-up. Figure 1A-C  
164 shows micrographs of pure FaSSIF, a precipitated tadalafil suspension in FaSSIF and a precipitated tadalafil suspension in FaSSIF  
165 with 0.5 % (w/v) HPMC after 14 min, respectively. The presence of 0.5 % (w/v) HPMC clearly decreased the number of  
166 precipitated particles in the frame observed after 14 min compared to the tadalafil suspension in FaSSIF. The difference in  
167 background colour is due to different illumination settings. Pure FaSSIF (Figure 1A) contained silhouettes of larger structures of  
168 approximately 100  $\mu\text{m}$ , however these silhouettes in pure FaSSIF were clearly distinguishable from the precipitate of tadalafil in  
169 FaSSIF. The darker blurry areas of the micrographs in Figure 1B and C were most likely precipitated particles out of focus.

170 The precipitate in pure FaSSIF (orange arrow, Figure 1B) had a round and compact core with a less dense outer layer (Figure  
171 1B), whereas the precipitate in FaSSIF with 0.5 % (w/v) HPMC (blue arrow, Figure 1C) appeared less dense and less regular.  
172 However, later appearing particles in pure FaSSIF (green arrow, Figure 1B) were similar to the less dense particles found in  
173 FaSSIF with HPMC.

174 Tadalafil has previously been shown to precipitate in a crystalline form (6), and similar differences in precipitate morphology  
175 have been observed for other compounds (7). For studying the morphology of the precipitate, Lindfors et al. (7) prepared  
176 supersaturated solutions of bicalutamide, let them stand for a minimum of 72 h to precipitate before taking images to analyse  
177 morphology and number of particles manually. Crystallization of the supersaturated bicalutamide system without PVP led to a  
178 star-like morphology of the particles, whereas more compact and spherical particles were formed in the presence of 0.01 % (w/w)  
179 PVP as PI (7). Furthermore, Lindfors et al. (7) reported morphology differences in precipitate particles formed without PI present  
180 dependent on the age of the particles, similar to the precipitate morphology observed for tadalafil (Figure 1B).



181  
182 **Figure 1.** Micrographs from the oCelloScope™. A: pure FaSSIF, B: 652  $\mu\text{g/mL}$  tadalafil in FaSSIF (t: 14.1 min), C: 652  $\mu\text{g/mL}$  tadalafil  
183 in FaSSIF with 0.5 % (w/v) HPMC (t: 14.8 min). t is the time after tadalafil was added to FaSSIF. The difference in background colour is  
184 due to different illumination settings between the runs. The orange and the green arrow illustrate an example of early and later appearing  
185 precipitate in pure FaSSIF, respectively. The blue arrow illustrates precipitate in FaSSIF with HPMC.

186

187

### 3.2 Single-particle analysis

188

189

190

191

192

193

194

195

196

As described above, precipitation comprises of two processes, namely nucleation and crystal growth. The appearance of the first particle can be used as a measure for  $t_{ind}$  and hence, to assess the effect of HPMC on nucleation. This time point was measured 20 - 24 times for each of the HPMC concentrations (Figure 2). The  $t_{ind}$  for tadalafil in FaSSIF was  $4.5 \pm 0.9$  min (Figure 2), and the addition of 0.001 % (w/v) HPMC to the dissolution medium did not significantly prolong this time ( $5.1 \pm 1.5$  min,  $p > 0.05$ ). In contrast, with the addition of 0.01, 0.1 or 0.5 % (w/v) of HPMC to the dissolution medium, the  $t_{ind}$  for tadalafil in FaSSIF was significantly prolonged compared to tadalafil in FaSSIF without HPMC at the same level of supersaturation (Figure 2). For 0.01 % (w/v) HPMC, the  $t_{ind}$  was prolonged to  $6.2 \pm 2.0$  min. Increasing the concentration of HPMC 10-fold further prolonged the  $t_{ind}$ , but the effect plateaued at a  $t_{ind}$  of about 9.5 min. A HPMC concentration of 0.5 % (w/v) resulted in a  $t_{ind}$  similar to the one observed with 0.1 % (w/v) HPMC present, albeit with a markedly reduced standard deviation (Figure 2).

197

198


199

200

201

202

It should be noted that the minimum detectable particle size is  $0.5 \mu\text{m}$  according to the technical specifications of the system, and thus the precipitation will have started already before any particles become visible. This will result in a lag time between the initial time of nucleation and the time point where the particles have reached a detectable size. However, as  $t_{ind}$  is defined here as the timepoint where the software identifies the first particle in focus, the determination was consistent for all measurements. The  $t_{ind}$  is used for comparative purposes, and not for exact modelling or extrapolation of initial nucleation, and hence, a consistent estimate is considered adequate.



203

204

205

206

207

**Figure 2.**  $t_{ind}$  for tadalafil in FaSSIF with different concentrations of predissolved HPMC observed with the single-particle analysis method (mean  $\pm$  SD). For each concentration of HPMC the experiment was repeated 20-24 times. The \* indicates a significant difference from the  $t_{ind}$  for tadalafil in FaSSIF without HPMC ( $p < 0.05$ ). The # indicates a significant difference from the  $t_{ind}$  for tadalafil in FaSSIF with 0.01 % (w/v) HPMC ( $p < 0.05$ ).

208

209

210

211

212

213


214

215

216

217

The growth of tadalafil particles in FaSSIF, plotted as a function of time, with different concentrations of predissolved HPMC is shown in Figure 3. The graph for each concentration of HPMC represents the growth of a single well-defined particle from 24 replications of the experiment. For tadalafil in FaSSIF without HPMC, the first particle appears after 5 min, corresponding to the  $t_{ind}$  in Figure 2 and hereafter, a linear growth in area is observed until the end of the study (22 min). The growth rate of tadalafil was not significantly decreased in FaSSIF with 0.001 % (w/v) HPMC. Maximal inhibition of the growth rate was reached with 0.01 % (w/v) HPMC, and no further decrease in the crystal growth was achieved with higher HPMC concentrations (0.1 and 0.5 % (w/v)). In a different setup, the size of a single representative particle has previously been used to investigate dissolution phenomena. Svanbäck et al. (20) showed an excellent correlation between the dissolution measured by UV spectroscopy and the reduction in particle size followed via video-microscopy, indicating that a single particle in principle can be used to explain the behaviour of a population of particles.



218

219

220

221

222

223

224

**Figure 3.** Area of single well-defined tadalafil particles in FaSSiF with different concentrations of predissolved HPMC as a function of time (mean  $\pm$  SD). For each of the HPMC concentrations the experiment was repeated 24 times, one well-defined particle was followed each time, and the individual area of the particle was calculated (n = 3-24). ● = 0.0 % (w/v), ■ = 0.001 % (w/v), ▲ = 0.01 % (w/v), ▼ = 0.1 % (w/v), ◆ = 0.5 % (w/v) HPMC.

225

### 3.3 Multi-particle analysis

226

227

228

229

230


231

232

233

Whilst the single-particle analysis focused on one early appearing particle, growth of only a selected particle may not be representative for the overall growth. To be able to describe the entire population of particles, and thus to include more data in the data analysis, an algorithm was developed to detect the appearing particles and calculate their areas (section 2.2.5). The induction time is defined as the first detection of a particle by the algorithm, and the same micrograph before and after segmentation is shown in Figure 4. The multi-particle analysis was able to find the majority of the particles. It is worth to note that the circular Hough transform used for particle counting was incapable of finding particles of which the geometric centers were outside the micrograph (Figure 4B). However, this was not considered an issue for the growth analysis as this was consistent and had no impact on the area measurement.





234


235 **Figure 4.** A: 652 µg/mL tadalafil in FaSSIF with 0.001 % (w/v) HPMC (t: 13.2 min), B: the same micrograph after segmentation, where  
236 the red section describes the area of the particles and the yellow circles are used to count the particles using the multi-particle analysis.

237

238 Using this algorithm, the  $t_{ind}$  for tadalafil in FaSSIF, without HPMC, was found to be  $4.6 \pm 0.7$  min (Figure 5). In the presence of  
239 0.001 % (w/v) HPMC no significant difference in  $t_{ind}$  was observed ( $5.4 \pm 1.1$  min,  $p < 0.05$ ), when compared to the  $t_{ind}$  for  
240 tadalafil in pure FaSSIF. A significantly prolonged  $t_{ind}$  was, however, observed for tadalafil in FaSSIF with 0.01 or 0.1 (w/v)  
241 HPMC ( $7.1 \pm 1.8$  min and  $9.2 \pm 1.7$  min, respectively), whereas a plateau effect was observed with the addition of 0.5 % (w/v)  
242 HPMC ( $9.5 \pm 1.1$  min,  $p < 0.05$ ), as this did not further prolong the  $t_{ind}$  significantly compared to 0.1% (w/v) HPMC. These  
243 induction times were consistent with the results observed for the single-particle analysis (Figure 2). In a recent study, the effect of  
244 HPMC (0.05 % w/v) on the nucleation of tadalafil in FaSSIF was investigated by a solvent shift method in a dissolution setup (6),  
245 and these authors also found that HPMC had a pronounced effect on the nucleation of tadalafil in FaSSIF and significantly  
246 prolonged the  $t_{ind}$ . These results correspond very well with those of the current study, even though the method used was very  
247 different. PI effects of HPMC have also been shown using amorphous solid dispersions as a method to induce supersaturation for  
248 tadalafil. An increase in HPMC concentration (1:1 – 1:8 w/w ratio of drug to polymer, corresponding to 0.013 % w/v – 0.024 %  
249 w/v HPMC in the dissolution medium) resulted in an increase in the maximum dissolved drug concentration achieved during a  
250 dissolution study and a retardation of drug precipitation in water (3).

251 A similar plateau effect of HPMC on the  $t_{ind}$  has previously been reported for the compound RS-8359, in a dissolution setup  
252 (13), where the precipitation was inhibited by adding 0.001 % (w/v) HPMC, but the effect did not further improve by addition of  
253 up to 0.1 % (w/v) HPMC.

254




255

256 **Figure 5.**  $t_{ind}$  for tadafafil in FaSSIF with different concentrations of predissolved HPMC observed with the multi-particle analysis  
 257 algorithm (mean  $\pm$  SD). For each concentration of HPMC the experiment was repeated 24 times. The \* indicates a significant difference  
 258 from the  $t_{ind}$  for tadafafil in FaSSIF without HPMC ( $p < 0.05$ ). The # indicates a significant difference from the  $t_{ind}$  for tadafafil in FaSSIF  
 259 with 0.01 % (w/v) HPMC ( $p < 0.05$ ).

260

261 The multi-particle analysis described the nucleation and subsequent crystal growth of the entire investigated area (Figure 6).  
 262 Until approximately 10 min, no significant difference in the growth of tadafafil particles with and without the presence of HPMC  
 263 was observed. However, after 10 min, a clear difference was observed in the growth trend of tadafafil particles in the different  
 264 investigated systems. With 0 and 0.001 % (w/v) HPMC present, a steep growth curve was observed after 10 min and continued  
 265 throughout the study (22 min). With 0.01 - 0.5 % (w/v) HPMC present, the nucleation and crystal growth of tadafafil seemed to be  
 266 inhibited for approximately 13 min, and after 15 min the growth of tadafafil particles increased. When analysing the area covered  
 267 by precipitated tadafafil, a maximum inhibitory effect therefore was obtained already with only 0.01 % (w/v) HPMC present,  
 268 which was also concluded from the single-particle analysis. A maximum inhibitory effect of HPMC around 0.01 % (w/v) has also  
 269 been described for RS-8359 (13), but a further increase in HPMC concentration lead to faster precipitation.




270

271 **Figure 6.** Percentage of the micrograph covered by tadafafil particles in FaSSIF with different concentrations of HPMC as a function of  
 272 time. The growth kinetics are shown as the area (%) of a micrograph covered by particles, calculated with the multi-particle analysis  
 273 (mean  $\pm$  SD,  $n=24$ ). ● = 0.0 % (w/v), ■ = 0.001 % (w/v), ▲ = 0.01 % (w/v), ▼ = 0.1 % (w/v), ◆ = 0.5 % (w/v) HPMC.

274

275 Another way to describe the particle population is to count the total number of particles, e.g. describing the number of nucleated  
 276 particles. The number of tadafafil particles at three different time points, 10.0 min, 14.5 min and 17.5 min is shown in Figure 7.

277 For FaSSIF without addition of HPMC and for the lowest HPMC concentration (0.001 % (w/v)), an increase in the particle count  
278 from 10 to 14.5 min was observed, but not from 14.5 to 17.5 min. However, for 0.01 % (w/v) HPMC, the rate of particle formation  
279 was constant throughout the three time points. For the high HPMC concentrations (0.1 - 0.5 % (w/v)) very few particles at 10 and  
280 14.5 min were observed however, there were significantly more particles at the last time point (17.5 min) ( $p < 0.05$ ). This  
281 corresponds well to the observations in Figure 5, where the first particles appear after approximately 10 min, for 0.1 and 0.5 %  
282 (v/v) HPMC. Hence, by adding 0.01 % (w/v) of HPMC to FaSSIF, it was possible to significantly inhibit both nucleation and  
283 crystal growth of tadalafil (Figure 6), however 0.1 % (w/v) HPMC was needed to obtain maximal inhibitory effect of HPMC on  
284 nucleation alone (Figure 5). For felodipine, it was possible to inhibit precipitation using HPMC concentrations two times lower  
285 than the ones used in the current study (26). Hence, as described in the introduction, the optimum polymer concentration for  
286 precipitation inhibition is drug dependent.



287

288 **Figure 7.** Histogram showing the number of particles (mean  $\pm$  SD) present at 10, 14.5 and 17.5 min ( $\pm$  0.5 min) for a supersaturated  
289 tadalafil suspension in FaSSIF with 0 – 0.5 % (w/v) HPMC (n = 24). ■ = 0.0 % (w/v), ■ = 0.001 % (w/v), ■ = 0.01 % (w/v), ■ = 0.1 %  
290 (w/v), ■ = 0.5 % (w/v) HPMC.

291

292 The developed method can be used as a screening tool to evaluate the effect of a PI on supersaturation. The effect of a PI on  
293 supersaturation of a given poorly water-soluble drug is valuable information during the preformulation phase. As described in the  
294 introduction, the effect of a PI is very drug specific, and it will often be necessary to screen several PI types, concentrations and  
295 grades before deciding on the optimal supersaturating system for a given drug. Thus, the information from this work provides  
296 qualitative knowledge about the effect of a PI on supersaturation, which can be used as an efficient and highly needed screening  
297 tool for the improvement of oral absorption of poorly water-soluble drugs using supersaturating systems.

298 Furthermore, the micrographs can give important information about the morphology and number of particles, whilst non-  
299 microscopy methods, e.g. dissolution and dynamic light scattering, do not provide the same level of detail or understanding of the  
300 system. For instance, morphological differences in the precipitating particles in the presence or absence of a PI can be an  
301 indication for molecular interactions between the drug and the PI. The possibility of using 96-well plates in an automated setup  
302 offers the potential for an effective high-throughput method where only small amounts of drug and PI are needed. Thus, this  
303 method is less time consuming and labour intensive, but yields comparable results to existing setups, e.g. conventional  
304 microscopy, where only one sample at a time can be measured (9, 19).

305

306 However, like any other setup, this method has its limitations. It takes the oCelloScope™ approximately 3 min to screen a 96-  
307 well plate. Determination of  $t_{ind}$  may require micrographs taken more frequently, and due to the lag time, this will be an estimate  
308 for  $t_{ind}$ . Nevertheless, for comparative measurements and as an initial tool to screen polymers for their PI effect, this is not  
309 considered a problem and the developed method appears appropriate.

310

311 3.4 Future perspective of the algorithm

312 The current image analysis is optimized for spherical particles; however, drug precipitates may have other shapes, for instance,  
313 carbamazepine forms needle-like structures and algorithms to account for this type of structures could be implemented, as  
314 proposed by Wu et al. (27). This proof-of-principle study has shown that it is possible to use the oCelloScope™ as a screening tool

315 of the effect of PIs in supersaturation studies. Future studies should include tracking of the particles over time which would enable  
316 conduction of single-particle analysis without any bias from manual selection. Optical flow algorithms like Farneback's flow  
317 algorithm (28) would probably solve this.

318

#### 319 **4. Conclusion**

320 A novel small scale high-throughput method has been developed to study the effect of precipitation inhibitors on poorly-water  
321 soluble drugs in supersaturated systems. A single-particle analysis was possible using commercially available software; however,  
322 to investigate the entire population of particles an algorithm for multi-particle analysis was designed. The data output was  
323 comparable between the two methods of analysis and yielded the same ranking of the inhibitory effect on precipitation of the  
324 different HPMC concentrations. Analysis of the data showed that 0.01 % (w/v) HPMC was sufficient to delay both nucleation and  
325 crystal growth of tadalafil in FaSSIF, however 0.1 % (w/v) HPMC was needed to obtain maximal inhibitory effect of HPMC on  
326 nucleation alone.

327

#### 328 **5. Acknowledgements**

329 This study was conducted as part of the Oral Biopharmaceutics Tools (ORBITO) project  
330 (<http://www.orbitoproject.eu>), funded by the Innovative Medicines Initiative (IMI) Joint Undertaking  
331 under Grant Agreement No. 115369. Furthermore, Line Hagner Nielsen would like to thank the Danish  
332 Research Council for Technology and Production (FTP), Project DFF-4004-00120B for financial  
333 support, and in addition, the Danish National Research Foundation (project DNRF122) and Villum  
334 Foundation's Center (Grant No. 9301) for Intelligent Drug Delivery and Sensing Using  
335 Microcontainers and Nanomechanics (IDUN) is acknowledged.

#### 336 **Abbreviations**

337 DMSO, dimethyl sulfoxide; DS, Degree of supersaturation; FaSSIF, Fasted State Simulated Intestinal  
338 Fluid; HPMC, Hydroxypropyl methyl cellulose; PI, Precipitation inhibitor;  $t_{ind}$ , Induction time

#### 339 **6. References**

340

- 341 1. Taylor, L. S.; Zhang, G. G. Physical Chemistry of Supersaturated Solutions and Implications for Oral  
342 Absorption. *Adv. Drug Delivery Rev.* 2016, 101, 122-142.
- 343 2. Jackson, M. J.; Kestur, U. S.; Hussain, M. A.; Taylor, L. S. Characterization of Supersaturated Danazol  
344 Solutions - Impact of Polymers on Solution Properties and Phase Transitions. *Pharm. Res.* 2016, 33(5),  
345 1276-1288.
- 346 3. Wlodarski, K.; Sawicki, W.; Haber, K.; Knapik, J.; Wojnarowska, Z.; Paluch, M.; Lepek, P.; Hawelek,  
347 L.; Tajber, L. Physicochemical Properties of Tadalafil Solid Dispersions - Impact of Polymer on the  
348 Apparent Solubility and Dissolution Rate of Tadalafil. *Eur. J. Pharm. Biopharm.* 2015, 94, 106-115.

- 349 4. Brouwers, J.; Brewster, M. E.; Augustijns, P. Supersaturating Drug Delivery Systems: The Answer to  
350 Solubility-Limited Oral Bioavailability? *J. Pharm. Sci.* 2009, 98(8), 2549-2572.
- 351 5. Gao, P.; Shi, Y. Characterization of Supersaturatable Formulations for Improved Absorption of Poorly  
352 Soluble Drugs. *AAPS J.* 2012, 14(4), 703-713.
- 353 6. Palmelund, H.; Madsen, C. M.; Plum, J.; Mullertz, A.; Rades, T. Studying the Propensity of Compounds  
354 to Supersaturate: A Practical and Broadly Applicable Approach. *J. Pharm. Sci.* 2016, 105(10), 3021-  
355 3029.
- 356 7. Lindfors, L.; Forssen, S.; Westergren, J.; Olsson, U. Nucleation and Crystal Growth in Supersaturated  
357 Solutions of a Model Drug. *J. Colloid Interface Sci.* 2008, 325(2), 404-413.
- 358 8. Madsen, C. M.; Boyd, B.; Rades, T.; Mullertz, A. Supersaturation of Zafirlukast in Fasted and Fed State  
359 Intestinal Media with and without Precipitation Inhibitors. *Eur. J. Pharm. Sci.* 2016, 91, 31-39.
- 360 9. Raghavan, S. L.; Trividic, A.; Davis, A. F.; Hadgraft, J. Crystallization of Hydrocortisone Acetate:  
361 Influence of Polymers. *Int. J. Pharm.* 2001, 212(2), 213-221.
- 362 10. Grammen, C.; Plum, J.; Van Den Brande, J.; Darville, N.; Augustyns, K.; Augustijns, P.; Brouwers, J.  
363 The Use of Supersaturation for the Vaginal Application of Microbicides: A Case Study With Dapivirine.  
364 *J. Pharm. Sci.* 2014, 103(11), 3696-3703.
- 365 11. Bevernage, J.; Forier, T.; Brouwers, J.; Tack, J.; Annaert, P.; Augustijns, P. Excipient-Mediated  
366 Supersaturation Stabilization in Human Intestinal Fluids. *Mol. Pharmaceutics.* 2011, 8(2), 564-570.
- 367 12. Warren, D. B.; Bergstrom, C. A.; Benameur, H.; Porter, C. J.; Pouton, C. W. Evaluation of the Structural  
368 Determinants of Polymeric Precipitation Inhibitors Using Solvent Shift Methods and Principle  
369 Component Analysis. *Mol. Pharmaceutics.* 2013, 10(8), 2823-2848.
- 370 13. Usui, F.; Maeda, K.; Kusai, A.; Nishimura, K.; Keiji, Y. Inhibitory Effects of Water-Soluble Polymers  
371 on Precipitation of RS-8359. *Int. J. Pharm.* 1997, 154(1), 59-66.
- 372 14. Raghavan, S. L.; Kiepfer, B.; Davis, A. F.; Kazarian, S. G.; Hadgraft, J. Membrane Transport of  
373 Hydrocortisone Acetate from Supersaturated Solutions; The Role of Polymers. *Int. J. Pharm.* 2001,  
374 221(1-2), 95-105.

- 375 15. Patel, D. D.; Anderson, B. D. Effect of Precipitation Inhibitors on Indomethacin Supersaturation  
376 Maintenance: Mechanisms and Modeling. *Mol. Pharmaceutics*. 2014, 11(5), 1489-1499.
- 377 16. Hsieh, Y. L.; Box, K.; Taylor, L. S. Assessing the Impact of Polymers on the pH-Induced Precipitation  
378 Behavior of Poorly Water Soluble Compounds Using Synchrotron Wide Angle X-Ray Scattering. *J.*  
379 *Pharm. Sci.* 2014, 103(9), 2724-2735.
- 380 17. Ilevbare, G.; Taylor, L. Liquid-Liquid Phase Separation in Highly Supersaturated Aqueous Solutions of  
381 Poorly Water-Soluble Drugs: Implications for Solubility Enhancing Formulations. *Cryst. Growth Des.*  
382 2013, 13(4), 1497-1509.
- 383 18. Bevernage, J.; Brouwers, J.; Brewster, M. E.; Augustijns, P. Evaluation of Gastrointestinal Drug  
384 Supersaturation and Precipitation: Strategies and Issues. *Int. J. Pharm.* 2013, 453(1), 25-35.
- 385 19. Wu, J. X.; Xia, D.; van den Berg, F.; Amigo, J. M.; Rades, T.; Yang, M.; Rantanen, J. A Novel Image  
386 Analysis Methodology for Online Monitoring of Nucleation and Crystal Growth During Solid State  
387 Phase Transformations. *Int. J. Pharm.* 2012, 433(1-2), 60-70.
- 388 20. Svanback, S.; Ehlers, H.; Yliruusi, J. Optical Microscopy As a Comparative Analytical Technique for  
389 Single-Particle Dissolution Studies. *Int. J. Pharm.* 2014, 469(1), 10-16.
- 390 21. Fredborg, M.; Andersen, K. R.; Jorgensen, E.; Droce, A.; Olesen, T.; Jensen, B. B.; Rosenvinge, F. S.;  
391 Sondergaard, T. E. Real-Time Optical Antimicrobial Susceptibility Testing. *J. Clin. Microbiol.* 2013,  
392 51(7), 2047-2053.
- 393 22. Kloefer, B.; van Hoogevest, P.; Moloney, R.; Martin Kuentz; Mathew L.S. Leigh, a. J. D. Study of a  
394 Standardized Teurocholate-Lecithin Powder for Preparing the Biorelevant Media FeSSIF and FaSSIF.  
395 *Dissolution Technol.* 2010, 6-13.
- 396 23. Shin-Etsu Chemical Co., Ltd. Molecular Weight and Degree of Polymerization. 2004 June.
- 397 24. Soille, P. *Morphological Image Analysis: Principles and Applications*. 2nd ed.; Springer-Verlag Berlin  
398 Heidelberg, 1999.
- 399 25. Davies, E. R. A Modified Hough Scheme for General Circle Location. *Pattern Recognit. Lett.* 1988, 7(1),  
400 37-43.

- 401 26. Alonzo, D. E.; Raina, S.; Zhou, D.; Gao, Y.; Zhang, G. G. Z.; Taylor, L. S. Characterizing the Impact of  
402 Hydroxypropylmethyl Cellulose on the Growth and Nucleation Kinetics of Felodipine from  
403 Supersaturated Solutions. *Cryst. Growth Des.* 2012, 12(3), 1538-1547.
- 404 27. Wu, J. X.; Kucheryavskiy, S. V.; Jensen, L. G.; Rades, T.; Müllertz, A.; Rantanen, J. Image Analytical  
405 Approach for Needle-Shaped Crystal Counting and Length Estimation. *Cryst. Growth Des.* 2015, 15(10),  
406 4876-4885.
- 407 28. Farnebäck, G. Two-frame motion estimation based on polynomial expansion. Bigun J, Gustavsson T,  
408 Eds.; *Image Analysis: 13th Scandinavian Conference, SCIA 2003 Halmstad, Sweden, June 29 – July 2,*  
409 *2003 Proceedings.* Springer-Verlag Berlin Heidelberg, 2003; pp 363-370.

410